Leon Lerman

CEO & Co-Founder, Cynerio
New York, New York,United States
Find Leon Lerman's Email
Find Leon Lerman's Phone

Who Is Leon Lerman?

Total Experience26 years
CompanyCynerio
CountryUnited States

Leon Solomon Lerman (June 27, 1925 – September 26, 2012) was a distinguished American molecular biologist and geneticist. He is most renowned for his groundbreaking discovery in the early 1960s that certain acridine-based mutagens, such as proflavine, act by intercalating themselves—inserting flatly—between the stacked base pairs of the DNA double helix. This model of intercalation provided crucial insights into DNA structure, its interaction with various molecules, and the mechanisms of mutagenesis. Later in his career, Lerman also pioneered the technique of Denaturing Gradient Gel Electrophoresis (DGGE) in the late 1970s and early 1980s. DGGE is a powerful method for separating DNA fragments based on differences in their melting behavior, which became invaluable for detecting mutations, polymorphisms, and analyzing microbial community diversity. He held positions at several prestigious institutions including the University of Colorado, Vanderbilt University, and the Massachusetts Institute of Technology (MIT).

How Did Leon Lerman's Career Path Shape Their Journey?

Leon Lerman's work history includes a series of influential roles in various companies. Here is a detailed list of his professional journey:

Cynerio - CEO & Co-Founder(2017 to Present)
Fast Company Executive Board - Official Member(2021 to Present)
Forbes Technology Council - Official Member & Contributor (2021 to Present)
Metapacket - VP of Sales(2016 to 2017)
RSA The Security Division of EMC - Sr. Sales Engineer / Sales(2013 to 2016)
ECI Telecom - Technical Presales Engineer(2011 to 2013)
8200 Unit IDF - Intelligence Officer(2007 to 2010)

What Are Leon Lerman's Key Achievements?

Discovery of DNA Intercalation Mechanism

In 1961, Lerman published seminal work demonstrating that acridine dyes (like proflavine) bind to DNA by inserting themselves between adjacent base pairs, a process he termed intercalation. This explained their mutagenic properties and significantly advanced the understanding of DNA-ligand interactions.

Development of Denaturing Gradient Gel Electrophoresis (DGGE)

Invented and developed DGGE in the late 1970s and early 1980s, a technique that allows for the separation of DNA molecules differing by as little as a single base substitution based on their melting properties in a chemical denaturant gradient. This became a key tool in genetics and microbial ecology.

Elected to the National Academy of Sciences

In recognition of his significant contributions to molecular biology and genetics, Leon Lerman was elected as a member of the U.S. National Academy of Sciences in 1981.

Research on DNA Condensation (Psi-DNA)

Investigated the phenomenon of psi (polymer and salt-induced) condensation of DNA, exploring how long DNA molecules can be tightly packaged into compact structures, relevant to DNA organization in viral capsids and cell nuclei.

What's Leon Lerman's Educational Background?

Bachelor’s Degree (BSc), Industrial Engineering and Management

The Open University of Israel - Year 2013

Degree Program

Mihlelet ORT Givat Ram - Year 2004

Buying Intent Signals for Leon Lerman

Highperformr Signals uncover buying intent and give you clear insights to target the right people at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance

Company Overview

Cynerio
Total employees180
HeadquartersRamat Gan
Founded2017

Cynerio is a healthcare cybersecurity company dedicated to protecting medical devices (IoMT), IoT, and OT systems within hospitals and healthcare facilities. Their platform provides comprehensive visibility into all connected devices, conducts risk assessments, detects anomalous behavior, and enables automated threat prevention and response. This helps healthcare organizations safeguard patient data, ensure patient safety, maintain operational continuity, and comply with industry regulations by securing the ever-expanding network of connected clinical and operational assets against cyber threats like ransomware and data breaches.

Cynerio Funding Information
Unknown - Total Funding Raised
$30M - Most recent funding amount
4 - Number of funding rounds
Jun 1, 2022 - Latest funding round
Lead Investors:
Accelmed
Elron Ventures
Global Founders Capital
Prytek
MTIP
OurCrowd
Aloe Ventures
FollowTheSeed

Highperformr's free tools for company research

Find contact info

Get verified emails, phone numbers, and LinkedIn profile details

Find similar contacts

Discover contacts with similar roles, seniority, or companies

Perform deep contact research

Uncover insights like skills, work history, social links, and more

Discover, research and enrich contacts with Highperformr — Smarter, Faster

Explore contacts in-depth — from verified emails and phone numbers to LinkedIn activity, job changes, and more — all in one powerful view.

Highperformr AI helps you surface the right people and enrich your CRM with live, accurate contact insights so your teams can connect faster and close smarter.

  • Track signals like job change, promotion, and LinkedIn activity
  • Enrich contacts with verified email, phone, and social data instantly
  • Automate enrichment and updates with powerful workflows
  • Sync enriched contact info directly into your CRM and tools

Thousands of contacts — including decision-makers, influencers, and ICP matches — are just a search away.

Thousands of companies, including, are just a search away.